Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There are yet limited real life data on outcomes following elective cardioversion in AF patients treated with NOACs. The aim of this study is to investigate the complications and the use of NOACs in AF patients undergoing cardioversion.
Study Type
OBSERVATIONAL
Enrollment
1,000
Incidence and predictors of thromboembolic complications
Time frame: 31 days after cardioversion of persistent AF
Incidence and predictors of bleeding
Time frame: 31 days after cardioversion of persistent AF
Number of recurrence of AF
Time frame: 31 days after cardioversion of persistent AF
Hemodynamic complications of cardioversion
Time frame: 31 days after cardioversion of persistent AF
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.